 Mesalamine
"Mesalamine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
| Descriptor ID |
D019804
|
| MeSH Number(s) |
D02.241.223.100.380.800.050.540 D02.241.511.390.700.050.500 D02.755.410.700.050.500
|
| Concept/Terms |
Mesalamine- Mesalamine
- m-Aminosalicylic Acid
- m Aminosalicylic Acid
- 5-Aminosalicylic Acid
- 5 Aminosalicylic Acid
- Mesalazine
- meta-Aminosalicylic Acid
- meta Aminosalicylic Acid
Asacolon- Asacolon
- Celltech Brand of Mesalamine
Ascolitin- Ascolitin
- Sanofi Synthelabo Brand of Mesalamine
- Henning Berlin Brand of Mesalamine
Canasa- Canasa
- Salofalk
- Provalis Brand of Mesalamine
- Falk Brand of Mesalamine
- Farmasa Brand of Mesalamine
- Axcan Brand of Mesalamine
- Antigen Brand of Mesalamine
Claversal- Claversal
- SmithKline Brand of Mesalamine
- Merckle Brand of Mesalamine
Fivasa- Fivasa
- Norgine Brand of Mesalamine
Lixacol- Lixacol
- Schering-Plough Brand of Mesalamine
- Schering Plough Brand of Mesalamine
Mesasal- Mesasal
- GlaxoSmithKline Brand of Mesalamine
Novo-5 ASA- Novo-5 ASA
- Novo 5 ASA
- Novo5 ASA
- Novopharm Brand of Mesalamine
Pentasa- Pentasa
- Ferring Brand of Mesalamine
- Yamanouchi Brand of Mesalamine
- Allphar Brand of Mesalamine
Rowasa- Rowasa
- Solvay Brand of Mesalamine
Asacol- Asacol
- Procter & Gamble Brand of Mesalamine
- Byk Brand of Mesalamine
|
Below are MeSH descriptors whose meaning is more general than "Mesalamine".
Below are MeSH descriptors whose meaning is more specific than "Mesalamine".
This graph shows the total number of publications written about "Mesalamine" by people in this website by year, and whether "Mesalamine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1989 | 0 | 1 | 1 | | 1990 | 0 | 2 | 2 | | 1993 | 0 | 3 | 3 | | 1994 | 0 | 1 | 1 | | 1995 | 0 | 3 | 3 | | 1997 | 1 | 0 | 1 | | 1998 | 2 | 0 | 2 | | 1999 | 1 | 0 | 1 | | 2000 | 1 | 3 | 4 | | 2001 | 1 | 1 | 2 | | 2002 | 0 | 2 | 2 | | 2003 | 5 | 1 | 6 | | 2004 | 4 | 2 | 6 | | 2005 | 6 | 1 | 7 | | 2006 | 3 | 3 | 6 | | 2007 | 4 | 0 | 4 | | 2008 | 5 | 1 | 6 | | 2009 | 2 | 0 | 2 | | 2010 | 1 | 0 | 1 | | 2011 | 4 | 0 | 4 | | 2012 | 2 | 0 | 2 | | 2013 | 1 | 0 | 1 | | 2014 | 0 | 2 | 2 | | 2016 | 3 | 1 | 4 | | 2017 | 0 | 1 | 1 | | 2018 | 1 | 0 | 1 | | 2019 | 0 | 2 | 2 | | 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Mesalamine" by people in Profiles.
-
Narula N, Aruljothy A, Alshahrani AA, Fadida M, Al-Saedi M, Marshall JK, Rubin DT, Christensen B. Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission. Aliment Pharmacol Ther. 2020 12; 52(11-12):1676-1682.
-
Gupta N, Hanauer SB. Too Soon to Discard 5-ASAs? Am J Gastroenterol. 2019 03; 114(3):534-535.
-
Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019 03; 114(3):384-413.
-
Setia N, Alpert L, van der Sloot KW, Colussi D, Stewart KO, Misdraji J, Khalili H, Lauwers GY. Lymphocytic colitis: pathologic predictors of response to therapy. Hum Pathol. 2018 08; 78:1-7.
-
Rubin DT, Cohen RD, Sandborn WJ, Lichtenstein GR, Axler J, Riddell RH, Zhu C, Barrett AC, Bortey E, Forbes WP. Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis. 2017 Jul 01; 11(7):785-791.
-
Bosworth BP, Sandborn WJ, Rubin DT, Harper JR. Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies. Inflamm Bowel Dis. 2016 08; 22(8):1881-6.
-
Lim WC, Wang Y, MacDonald JK, Hanauer S. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev. 2016 Jul 03; 7:CD008870.
-
Hanauer SB. Oral or Topical 5-ASA in Ulcerative Colitis. Dig Dis. 2016; 34(1-2):122-4.
-
Rubin DT, Bradette M, Gabalec L, Dobru D, Márquez J, Inglis S, Magee E, Solomon D, D'Haens G. Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial. J Crohns Colitis. 2016 Aug; 10(8):925-33.
-
Chapman CG, Rubin DT. The potential for medical therapy to reduce the risk of colorectal cancer and optimize surveillance in inflammatory bowel disease. Gastrointest Endosc Clin N Am. 2014 Jul; 24(3):353-65.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|